Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AVIR
ATEA PHARMACEUTICALS, INC.
NASDAQ
$5.70
▲ UP 3.83% (0.21)

KEY STATISTICS

Market Cap$456.95 M
52w High$6.45
52w Low$2.78
Dividend Yield—
Frequency—
P/E-2.70
Volume289.92K
Shares Out.80.03M

COMPANY

LEADERSHIP

Jean-Pierre Sommadossi
CHIEF EXECUTIVE
Jean-Pierre Sommadossi

COMPENSATION 2026

Salary$703,490
Stock Awards$1,315,800
Incentive Plan Pay$422,094
All Other Comp.$0
Total$3,403,752

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 30, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
55

PRICE TARGET

Target High$10.00
Target Low$7.00
Target Median$8.50
Target Consensus$8.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$50.45M
NOV
11
WED

PRICE

$5.70 ▲ UP 3.83% (+$0.21)
$5.55$5.63$5.709:33 AM10:37 AM11:42 AM12:46 PM1:50 PM2:55 PM3:59 PM5.70

About Atea Pharmaceuticals, Inc.

https://www.ateapharma.com ↗

Atea Pharmaceuticals is a Boston-based clinical-stage biopharma developing antiviral therapeutics like AT-527 for COVID-19 and other candidates targeting viral infections such as dengue, HCV, Zika, and yellow fever.

INDUSTRY

Biotechnology

A PRODUCT ATEA PHARMACEUTICALS, INC. IS KNOWN FOR

Bemnifosbuvir and Ruzasvir (combination regimen)
Bemnifosbuvir and Ruzasvir (combination regimen)

Atea Pharmaceuticals is developing an investigational all-oral, fixed-dose combination of bemnifosbuvir and ruzasvir for HCV, currently in Phase 3 trials with results expected in 2026, aiming to provide a potentially best-in-class treatment.

COMPETITORS

COMPETITOR
ABBV COMPARE
COCP COMPARE
GILD COMPARE
MRK COMPARE
VIR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
85
LISTED HERE
14
RANKED BY POSITION SIZE
VTS.AX
0.00% · 2.0M
IWM
0.01% · 1.8M
SCHA
0.01% · 342.8K
DFAS
0.01% · 263.9K
AVSC
0.03% · 151.0K
R2US.L
0.01% · 142.6K
OMFS
0.25% · 129.5K
FESM
0.01% · 94.4K
XRS2.F
0.01% · 66.2K
RSSL
0.01% · 33.7K
SILX
0.56% · 26.7K
GERM
0.66% · 18.4K
URTY
0.00% · 2.9K
JHMH
0.01% · 88

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.15%
HOLDERS
176
TOP 12 OF 176 · RANKED BY POSITION SIZE
Fmr LLC
12.0M sh · $55.82M
Blackrock Inc.
9.1M sh · $30.19M
Blackrock, Inc.
8.7M sh · $40.55M
Bml Capital Management, LLC
7.5M sh · $26.74M
Tang Capital Management LLC
4.8M sh · $14M
Vanguard Group Inc
4.7M sh · $13.66M
Bain Capital Life Sciences Investors, LLC
2.5M sh · $8.87M
Acadian Asset Management LLC
2.0M sh · $9.46M
Geode Capital Management, LLC
2.0M sh · $9.11M
Two Sigma Investments, LP
1.9M sh · $10.03M
State Street Corp
1.8M sh · $6.37M
Dimensional Fund Advisors LP
1.5M sh · $4.47M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
BERGER FRANKLIN M
Sale · 29.6K shares
2026-06-18
★
DIRECTOR
Polsky Bruce
Sale · 29.6K shares
2026-06-18
★
DIRECTOR
Murphy Polly A.
Purchase · 29.6K shares
2026-06-18
★
DIRECTOR
Lucidi Bruno
Sale · 29.6K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
EQUAL WEIGHT 1
OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
Morgan Stanley EQUAL WEIGHT Evercore ISI Group OUTPERFORM

SECTORS PEERS

PEERPRICE
ACHV$8.38COMPARE
ALLO$1.92COMPARE
ARCT$16.73COMPARE
ENTA$13.78COMPARE
VNDA$5.51COMPARE
TRDA$7.13COMPARE
PYXS$3.69COMPARE
VYGR$3.51COMPARE